2020

Democratizing Access to Cancer-Related Proteomic Data

The US National Cancer Institute (NCI) has launched the Proteomic Data Commons (PDC), a next-generation proteomic data repository that will facilitate data access, sharing, and analysis to speed development of precision-medicine therapies for cancer. Housed within the NCI’s Cancer Research Data Commons (CRDC), PDC hosts several multiomic data sets that have corresponding genomics and imaging data elsewhere, simplifying their access to enable integrative research. Increase Access to Enable Discovery Mass spectrometry (MS)–based proteomic profiling for pancancer analyses could enhance our…

Breaking the Bottlenecks: Accelerating Viral Vector Bioanalysis in Downstream Processing

The rise in popularity of viral-vector–based gene therapies and SARS-CoV-2 vaccines has created a shortage of manufacturing capacity, driving efficiency improvements to avoid bottlenecks in bioanalysis to support culture optimization and bioprocessing steps. To improve workflows in bioanalytical assay development and sample analysis, more efficient methods are needed that include higher throughput, simpler and more streamlined sample assay methods, wide dynamic ranges, and efficient data processing and interpretation. Gyrolab™ microfluidic, nanoliter-scale immunoassay systems provide an innovative, robust solution to high-performance…

Peptide Therapies: Designing a Science-Led Strategic Quality Control Program

Peptide therapeutics are a unique class of pharmaceuticals. They can fall into one or more regulatory categories: as conventional chemical molecules, biological entities, or biosimilars. Developing a well–thought-out quality control (QC) strategy is key to meeting development milestones and complying with evolving regulatory requirements. Safety assessment is critical because slight changes in the structure, physicochemical properties, stability, and impurity profile of a peptide can provoke an adverse immune response. A robust analytical QC program should be conducted in laboratories that…

Upstream Intensification with High-Density Cell Cryopreservation

In all bioprocess stages, developers and manufacturers aim to intensify as many steps as possible. For upstream processes, the result can be significant productivity gains with an evolution of bioreactor train design that takes advantage of higher titers to compress the train and intensify production outputs. Upstream intensification of production-scale bioreactors has driven bioprocess productivity evolution for several years. Interest has been growing in what can be achieved with laboratory-scale cell expansion, which has remained a fairly static process involving…

Easy Perfusion for Anchorage-Dependent Cell Culture Using an Eppendorf Vessel with Microcarrier Spin Filter

Anchorage-dependent cells such as Vero cells are used widely as a platform for viral vaccine production. Perfusion bioprocesses enable a constant addition of nutrients and removal of byproducts while cells are in a bioreactor. That results in cell densities that are higher than those for conventional batch or fed-batch processes. In the study herein, Eppendorf researchers tested the suitability of a spin filter as a cell-retention device. They cultivated Vero cells on Cytodex 3 microcarriers (10 g/L) in an Eppendorf…

Mitigating Raw-Material Risks During a Pandemic

The COVID-19 crisis has reinforced the importance of having a strong supply chain and a risk-management and business-continuity plan. How can you mitigate your raw material risk, especially during a pandemic? Risks When Choosing a Raw Material Supplier: How do you select your critical raw-material suppliers? What selection criteria and which risks have you identified? To understand risks related to supply, demand, material supplier capacities, and so on, you need information that can come only from communicating with your supplier…

Continuous Biomanufacturing Implementation: Using an Intensified and Integrated Bioprocess Platform

Recent world events have demonstrated now more than ever the growing demand for pharmaceutical biologics that can be made rapidly and in high volumes yet somehow remain affordable. Hence, there is an urgent need to develop a next-generation biomanufacturing solution that provides high-yield, high-quality drug products and is highly flexible and cost-effective. Herein we describe the WuXi Biologics ultrahigh productivity platform (WuXiUP), an intensified perfusion culture process developed to meet the aforementioned need. WuXiUP adopts process-intensification strategies on to traditional…

Simplifying Progress

Never has there been a more critical time to be a company delivering technologies and expertise that helps get new biologics and vaccines to patients faster. Sartorius is that company. Working in partnership with scientists, we help turn research discoveries into real-world medicines. Our bioprocessing equipment and know-how are called on every day to create biologics that treat debilitating diseases, including cancer and arthritis, and make affordable vaccines to prevent common infections. When global organizations such as the Jenner Institute…

Custom Affinity Solutions from Astrea Bioseparations

Astrea Bioseparations Ltd. (Astrea) is the only bioseparations company to offer ligand discovery and adsorbent development services coupled with manufacture and supply of bulk quantities of chromatography adsorbents and production of prepacked chromatography columns to good manufacturing practice (GMP) standards. Our synthetic affinity ligands have been proven over 30 years through numerous examples of successful discovery, development, and delivery of novel affinity adsorbents. Our technology is designed to capture and purify selective target biomolecules — including recombinant proteins, human plasma…

Ensuring Confidence in the Supply of Single-Use Connections

With 25 years’ experience in the biopharmaceutical industry, CPC proudly engineers single-use connection technologies that address biopharmaceutical manufacturers’ requirements for reliability, assurance of sterility, and ease of use. CPC’s innovative line of genderless AseptiQuik sterile connectors allows manufacturers to make quick and easy sterile connections, even in nonclassified environments. All genderless AseptiQuik connectors feature an easy-to-use three-step process that greatly minimizes the risk of operator error and ensures that sterility will be maintained both before and after connection. Fill out…